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Abstract
Mycobacterium protein tyrosine phosphatase B (mPTPB) is a potential drug target of Tuberculosis 
(TB). Small molecule inhibitors of mPTPB could be a treatment to overcome emerging TB drug 
resistance. Using a Diversity-Oriented Synthesis (DOS) strategy, we successfully developed a 
salicylic acid based and drug-like mPTPB inhibitor with an IC50 of 2 μM and >20-fold specificity 
over many human PTPs, making it an excellent lead molecule for anti-TB drug discovery. In 
addition, DOS generated bicyclic salicylic acids are also promising starting points for acquiring 
inhibitors targeting other PTPs.
Protein tyrosine phosphatases (PTPs) have emerged as the next generation drug targets due 
to their complementary roles to protein tyrosine kinases in controlling protein tyrosine 
phosphorylation levels.[1] Small molecule PTP inhibitors thus possess enormous therapeutic 
potentials. However, there are two major challenges in PTP inhibitor development: 
specificity and cell permeability, due to conserved and highly positively charged active 
sites.[2] Consequently, most existing PTP inhibitors mimic the negatively charged pTyr 
substrate.[1d,3] We discovered that salicylic acid could serve as a novel pTyr mimetic, 
affording PTP inhibitors with excellent potency, specificity, and cell permeability.[4] To 
expand the salicylic acid based chemistry, we sought to employ Diversity-Oriented 
Synthesis (DOS)[5] strategy to develop salicylic acid based PTP inhibitors with novel and 
diverse structures, and more importantly, drug-like properties.
Tuberculosis (TB) is a worldwide threat to public health with 9 million new infections and 
1.8 million deaths yearly.[6] Existing TB treatments require administration of antibiotics 
targeting mycobacterial RNA transcription, protein translation, and cell wall biogenesis for 
6–9 months.[7] The lengthy treatment often leads to patient noncompliance, which 
contributes to the emergence of multidrug-resistant (MDR) and extensively resistant (XDR) 
TB. Thus there is urgent need to develop new and more effective therapies against TB.[8] 
Mycobacterium protein tyrosine phosphatase B (mPTPB) was identified as a promising 
target for novel anti-TB agents. It is secreted into host macrophages by Mtb and is a 
virulence factor to attenuate host immune responses.[9] Deletion of mPTPB impaired the 
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ability of the mutant strain to survive in interferon-γ (IFN-γ) activated macrophages and 
severely reduced the bacterial load in a clinically-relevant guinea pig model.[10] Hence small 
molecules that inhibit mPTPB posses great potentials as anti-TB agents with nonoverlapping 
mechanism of action with existing drugs.[4c] Although a handful of mPTPB inhibitors have 
been reported, they often have high molecular weight, high lipophilicity, and flexible 
structures, and are thus not ideal lead molecules.[11] Herein we report our DOS strategy in 
generating novel salicylic acid based mPTPB inhibitors with good potency, specificity, cell 
activity, and more importantly, lean and compact structures with drug-likeness.
Given that bicyclic salicylic acid are more active than salicylic acid itself in inhibiting PTP 
activity as a result of enhanced interactions with the PTP active site,[4] our target molecules 
in DOS strategy encompass a range of novel bicyclic heterocycles (Fig. 1). To this end, we 
aim to install heteroatoms in adjacent positions on the parent benzene ring of salicylic acid, 
which furnishes molecular handles for the generation of the second heterocycles. The 
substituents can be amino, hydroxyl, halogen, and other groups that are easily 
functionalized. As a proof of concept, we synthesized protected salicylic acids with 
substituents of 4-hydroxy-5-amino (1), 4,5-diamino (2), 4-amino-5-iodo (3), and 4-amino-3-
iodo (4). The syntheses of these intermediates are straightforward from commercially 
available starting materials (Scheme 1). 1 was obtained from 4-hydroxy salicylic acid in a 
sequence of nitration, protection, and reduction with 46% overall yield. Similarly, 2 was 
prepared in 5 steps including acetylation, nitration, hydrolysis, esterification, and reduction, 
with overall yield of 23%. Although iodine gave amino and iodo substituted 3 and 4 in low 
yields, using 1.1 equivalents of iodine monochloride successfully delivered products 3 and 4 
in excellent yield, which were easily separated by flash chromatography.
Intermediates 1–4 were treated with various cyclization reagents to make the second 
heterocyclic rings, which were then hydrolyzed in 10% LiOH/MeOH (v/v=1:1) to afford 
bicyclic salicylic acids (Scheme 2). Examples from intermediate 1 include isothiocynates for 
aminooxazole 5, triphosgene for cyclic carbamate 6, chloro acetic chloride and bromo acetic 
acid methyl ester for six membered lactam 7 and lactone 8, and a sequence of benzaldehyde 
and DDQ for oxazole 9.[12] From intermediate 2, the method for synthesizing oxazole 9 
failed to give cyclised product 10, however, treatment of 2 with benzaldehyde in the 
presence of ammonium acetate successfully afforded benzimidazole 10 in excellent yield, 
and oxygen in the air was the oxidant for cycliation.[13] Intermediates 3 and 4 were reacted 
with phenyl isothiocynate to give aminobenzthiazole compounds 11a and 11b, 
respectively.[14,15] The reaction occurs in a sequence of thiourea formation and Cu(I) 
catalyzed S-arylation, and TBAB was proposed to play a role as ligand and phase-transfer 
catalyst. All products generated by the DOS strategy were obtained in moderate to good 
yields, and were purified by reversed phase HPLC to give structurally diverse bicyclic 
heterocycles with salicylic acid moiety. The ability of the compounds to inhibit the mPTPB 
catalyzed para-nitrophenyl phosphate hydrolysis was evaluated. Several structural motifs, 
including benzoxazole 9, benzimidazole 10, and aminobenzthiazole 11a, stand out as the 
most active among the DOS generated bicyclic salicylic acids 5–11, with IC50 values from 
20 to 30 μM, while bicycles such as 6, 7, 8, did not exhibit activity at 100 μM, likely due to 
lack of aromaticity. Interestingly, 11a is 3-fold more active than its close analogues 11b, 
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indicating that the hydroxyl group on the parent phenyl ring contributes to the affinity, and 
its location on the benzene ring influences compound's activity against mPTPB. Compound 
11a's easy access, good activity, low molecule weight (MW = 286), coupled with the 
prevalence of the aminothiazole motif in FDA approved drugs such as Dasatinib and Norvir, 
make it ideal for further elaboration to develop drug-like mPTPB inhibitors with improved 
potency.
Thus, a focused library of aminothiazole-salicylic acids was prepared by reacting precursor 
3 with a set of aryl isothiocynates. Generally, o, m, or p-substituted phenyl isothiocyanates 
with either electron donating or withdrawing properties, as well as 1-naphthyl 
isothiocyanate, were tolerated to afford products in moderate to good yields, except that 
alkyl isothiocynates did not react with 3 under the same reaction conditions (Fig. 2). All 
hydrolyzed products were purified by HPLC to ensure high purity. SAR analysis indicated 
that a substituent at m position of isothiocynate is most beneficial, and compound 11h with 
m-bromo was found to be the most potent mPTPB inhibitor with an IC50 of 2.0 μM, 
representing a 12-fold increase in comparison to 11a. It should be noted that salicylic acid 
exhibits an IC50 value of 55±8 mM for mPTPB. Thus, compound 11h improved salicylic 
acid mPTPB inhibitory activity by 27,500 fold. Subsequent kinetic studies revealed that it is 
a noncompetitive inhibitor against pNPP with a Ki of 2.2±0.1 μM (Fig. S1, ESI†). To 
determine the specificity of 11h towards mPTPB, its inhibitory activity against 
representative human PTPs including cytosolic PTPs, PTP1B, SHP2, SHP1, PTP-Meg2, the 
receptor-like PTPs, CD45 and PTPε, and the dual specificity phosphatases VHR and 
Laforin, were measured. As shown in Table 1, 11h is highly selective for mPTPB, 
exhibiting over 20-fold preference against these PTPs. The basis of the high specificity of 
11h was also studied by molecular modeling, which shows that salicylic acid head group in 
11h strongly interacts with mPTPB active site P-loop residues CFAGKDR (Fig. 3), 
however, 11h has weaker interactions with cognate residues in the P-loop of PTP1B 
(highlighted in green color). This has been validated by sequence alignment showing that 
CFAGKDR is unique to mPTPB in comparison to many human PTPs (Fig. S2, S3, ESI†). In 
addition, benzthiazole and 3-bromo benzene of 11h interact with helices α3A, α7 and α8 of 
mPTPB, which are not present in human PTPs such as PTP1B and VHR (Fig. S3, ESI†). 
mPTPB secreted by Mtb down-regulates Erk1/2 activation in macrophage cells to block IL-6 
production, while up-regulates Akt to promote survival, and mPTPB inhibitors can rescue 
these processes.[4c] Gratifyingly, 11h increased Erk1/2 and decreased Akt phosphorylations 
in mPTPB transfected Raw264.7 cells at 5 μM, 10 μM, in a dose dependent manner. By 
contrast, 11a (IC50 = 25 μM) has no such effects at 10 μM, validating 11h's excellent 
cellular activity in targeting mPTPB (Fig. S4, ESI†).
In summary, we have successfully applied a DOS strategy for the discovery of a range of 
novel bicyclic salicylic acids as mPTPB inhibitors. A subsequent focused library provided 
compound 11h with improved potency and excellent specificity for mPTPB. With 
advantages of efficient synthesis, low molecular weight and excellent cell activity, it serves 
as a promising lead molecule for anti-TB drug discovery targeting mPTPB. Given the 
†Electronic Supplementary Information (ESI) available: See DOI: 10.1039/b000000x/
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favourable pharmacological properties exhibited by the salicylic acid pharmacophore, the 
bicyclic scaffolds generated by the DOS strategy should also be good starting points for the 
development of drug-like inhibitors targeting other PTPs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Structure of salicylic acid as pTyr mimetic and the design of DOS for discovery of novel 
and drug-like mPTPB inhibitors.
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Fig. 2. 
Structures of aminothiazole salicylic acids and their activities against mPTPB.
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Fig. 3. 
Proposed interactions between 11h and mPTPB. 11h (cyan) and mPTPB residues (gray) 
within 5Å distance are shown in stick, polar interactions are highlighted in dotted yellow 
line. The P-loop of PTP1B (green, side chains in blue) was superimposed into 11h•mPTPB 
complex, showing that 11h has weaker interactions with the P-loop of PTP1B.
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Scheme 1. 
The synthesis of 3,4 or 4,5-disubstituted intermediates as precursors for DOS.
He et al. Page 9
Medchemcomm. Author manuscript; available in PMC 2015 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Scheme 2. 
DOS of various bicyclic salicylic acids as mPTPB inhibitors. Reaction condition c: 10% 
LiOH/MeOH (v/v=1:1), 80 °C, 1 h.
He et al. Page 10
Medchemcomm. Author manuscript; available in PMC 2015 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
He et al. Page 11
Table 1
Specificity studies of compound 11h against a panel of PTPs.
Enzyme IC50 (μM) Enzyme IC50 (μM)
mPTPB 2±0.1 CD45 >>100
PTP1B 65±1 PTPε >> 400
SHP2 50±l VHR 43±3
SHP1 78±8 Laforin 56±3
PTP-Meg2 69±2
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